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Study question:  28 
Is a clinical trophectoderm (TE) biopsy a suitable predictor of chromosomal 29 
aneuploidy in blastocysts? 30 
 31 
Summary answer:  32 
In the analyzed group of blastocysts, a clinical TE biopsy was an excellent 33 
representative of blastocyst karyotype in cases of whole chromosome 34 
aneuploidy, but in cases of segmental (sub-chromosomal) aneuploidy, a TE 35 
biopsy was a poor representative of blastocyst karyotype.  36 
 37 
What is known already:   38 
Due to the phenomenon of chromosomal mosaicism, concern has been 39 
expressed about the possibility of discarding blastocysts classified as aneuploid 40 
by pre-implantation genetic testing for aneuploidy (PGT-A) that in fact contain a 41 
euploid Inner Cell Mass (ICM). Previously published studies investigating 42 
karyotype concordance between TE and ICM have examined small sample sizes 43 
and/or have utilized chromosomal analysis technologies superseded by Next 44 
Generation Sequencing (NGS). It is also known that blastocysts classified as 45 
mosaic by PGT-A can result in healthy births. TE re-biopsy of embryos classified 46 
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as aneuploid can potentially uncover new instances of mosaicism, but the 47 
frequency of such blastocysts is currently unknown.  48 
 49 
Study design, size, duration:  50 
45 patients donated 100 blastocysts classified as uniform aneuploids (non-51 
mosaic) using PGT-A by NGS (n=93 whole chromosome aneuploids, n=7 52 
segmental aneuploids). In addition to the original clinical TE biopsy used for 53 
PGT-A, each blastocyst was subjected to an ICM biopsy as well as a second TE 54 
biopsy. All biopsies were processed for chromosomal analysis by NGS, and 55 
karyotypes compared to the original TE biopsy.  56 
  57 
Participants/materials, setting, methods:  58 
Single IVF center with in-house PGT-A program and associated research 59 
laboratory.  60 
 61 
Main results and the role of chance: 62 
When one or more whole chromosomes were aneuploid in the clinical TE biopsy, 63 
the corresponding ICM was aneuploid in 90 out of 93 blastocysts (96.8%). When 64 
the clinical TE biopsy only contained segmental (sub-chromosomal) 65 
aneuploidies, the ICM was aneuploid in 4 out of 7 cases (57.1%). Blastocysts 66 
showing aneuploidy concordance between clinical TE biopsy and ICM were also 67 
aneuploid in a second TE biopsy in 86 out of 88 cases (97.7%). In blastocysts 68 
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displaying clinical TE-ICM discordance, a second TE biopsy was aneuploid in 69 
only 2 out of 6 cases (33.3%). 70 
 71 
 72 
Limitations, reasons for caution:  73 
All embryos in this study had an initial classification of ‘aneuploid’ and not 74 
‘euploid’ or ‘mosaic’. Therefore, the findings of this study refer specifically to a TE 75 
biopsy predicting aneuploidy in the remaining blastocyst, and cannot be 76 
extrapolated to deduce the ability of a TE biopsy to predict euploidy in the 77 
blastocyst.  No conclusions should be drawn from this study about a mosaic TE 78 
biopsy’s ability to predict the karyotype of the corresponding blastocyst. Caution 79 
should be exercised in generalizing the findings of the sample group of this study 80 
to the general IVF blastocyst population. The segmental aneuploidy group only 81 
contains 7 samples.  82 
 83 
Wider implications of the findings: 84 
The high rate of intra-blastocyst concordance observed in this study concerning 85 
whole chromosome aneuploidy contributes experimental evidence to the 86 
validation of PGT-A at the blastocyst stage. Concomitantly, the results suggest 87 
potential clinical value in reassessing blastocysts deemed aneuploid by TE re-88 
biopsy in select cases, particularly in instances of segmental aneuploidies. This 89 
could impact infertility treatment for patients who only have blastocysts classified 90 
as aneuploid by PGT-A available. 91 
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INTRODUCTION 102 
 103 
A number of clinical trials have reported improved IVF outcomes following the 104 
vetting of embryos for chromosomal abnormalities (Forman et al., 2013; Rubio et 105 
al., 2017; Scott et al., 2013; Yang et al., 2012), and yet the IVF community is still 106 
debating the appropriate use of preimplantation genetic testing for aneuploidy 107 
(PGT-A, previously called PGS) (Practice Committees of the American Society 108 
for Reproductive et al., 2018; Sermon et al., 2016). Skeptics of the technology 109 
condemn the assumption that a 5-10 cell biopsy is representative of the 110 
remaining embryo (Esfandiari et al., 2016; Gleicher and Orvieto, 2017). Indeed, 111 
the phenomenon of mosaicism, the condition of containing two or more cell lines 112 
with distinct chromosomal content (Taylor et al., 2014), provides a biological 113 
rationale for that concern. A karyotypic categorization of the trophectoderm (TE), 114 
the precursor to the placenta, might therefore not always be predictive of the 115 
inner cell mass (ICM), which gives rise to the fetus. 116 
One of the potential consequences of misclassification of embryos during 117 
PGT-A is the deselection of viable embryos when a blastocyst is deemed 118 
aneuploid by TE biopsy but in fact contains a euploid ICM (Esfandiari et al., 119 
2016; Schoolcraft et al., 2017; Vera-Rodriguez and Rubio, 2017). Some patients 120 
are only capable of producing embryos classified as aneuploid by PGT-A even 121 
after repeated IVF cycles, particularly with advanced age (Franasiak et al., 2014). 122 
Such cases invariably lead to the abandonment of infertility treatment.   123 
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Previous studies investigating rates of TE-ICM chromosomal concordance 124 
(expertly reviewed by Capalbo and Rienzi), while extremely valuable, have relied 125 
on limited sample sizes or methodologies that have recently been superseded by 126 
higher resolution genetic testing platforms (Capalbo and Rienzi, 2017). Next 127 
Generation Sequencing (NGS), has been heralded as a PGT-A technique with 128 
superior sensitivity for chromosomal mosaicism compared to aCGH, qPCR or 129 
SNP array (Fragouli et al., 2017; Harton et al., 2017; Maxwell et al., 2016; Munne 130 
et al., 2017; Munne and Wells, 2017) and has also been reported as highly 131 
effective in detecting segmental (i.e. sub-chromosomal) losses and gains with 132 
higher precision than previous methods (Lai et al., 2017).  133 
The purpose of this study was specifically to test the hypothesis that a 134 
blastocyst embryo classified as aneuploid by NGS-based PGT-A correctly 135 
predicts the ploidy of the ICM in the majority of cases. Furthermore, by analyzing 136 
a second TE biopsy we determined the frequency of blastocysts originally 137 
classified as aneuploid that could be redefined as mosaic by re-biopsy. 138 
  139 
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 140 
MATERIALS AND METHODS 141 
 142 
Embryos and clinical PGT-A analysis by NGS  143 
 144 
Blastocysts derived from patients seeking infertility treatment were 145 
generated by in vitro fertilization and embryo culture as previously described 146 
(Victor et al., 2017), and were evaluated using the Gardner system (Gardner and 147 
Schoolcraft, 1999). As part of the embryo selection process, a clinical 5-10 cell 148 
TE biopsy was collected and blastocysts were vitrified. The clinical TE biopsies 149 
were subjected to whole genome amplification (WGA) with SurePlex reagents 150 
(Illumina) followed by NGS-based PGT-A using Illumina’s VeriSeq kit (Illumina) 151 
on a MiSeq system (Illumina) according to the manufacturer’s protocol and 152 
described in detail elsewhere (Vera-Rodriguez et al., 2016). For quality control, 153 
only samples satisfying the following cutoffs were used: number of Reads 154 
Passing Filter: >0.25M; Average Q-Score: >30; Alignment Score: >30; DLR 155 
(derivative log ratio): <0.4. Karyotype profiles were evaluated independently by 156 
three analysts and consensus determined. Copy number variation (CNV) for 157 
each chromosome was scored in Bluefuse Multi Analysis Software (Illumina) 158 
according to guidelines defined by the Preimplantation Genetic Diagnosis 159 
International Society (PGDIS), accessible at 160 
‘http://www.pgdis.org/docs/newsletter_071816.html’: Profiles with copy number 161 
scale values <1.2 and >2.8 were recorded as aneuploid, those with values 162 
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between 1.8 and 2.2 were recorded as euploid, and all others were recorded as 163 
mosaic. These guidelines reflect the detection range of mosaicism by NGS PGT-164 
A, validated in various cell- and DNA-mixing experiments (Fragouli et al., 2017; 165 
Maxwell et al., 2016; Munne et al., 2017; Munne and Wells, 2017). The resolution 166 
of VeriSeq NGS is validated to detect segmental (sub-chromosomal) 167 
aneuploidies of 20Mb or larger by the manufacturer, although detection of 168 
regions down to 1.81Mb have been reported using this platform (Zheng et al., 169 
2015). In our center, we consider ‘aneuploidy’ to encompass both whole and 170 
segmental chromosome abnormalities.  171 
Supernumerary blastocysts classified as ‘aneuploid’ (no mosaics) by PGT-172 
A were donated to science by signed informed consent by 45 patients (average 173 
age of 36.5 ± 5.7) and de-identified. This study was approved by the institutional 174 




ICM and Second TE Biopsy Collection and Analysis 179 
 180 
ICM biopsies were isolated from vitrified-warmed blastocysts as outlined in the 181 
legend for Fig. 1A, basing the technique on a protocol described previously 182 
(Taylor et al., 2016) but omitting the exposure of samples to Ca2+/Mg2+-free 183 
medium. Immediately following ICM biopsy an additional TE biopsy was 184 
collected. All biopsies were washed three times to clear any loose cells or cellular 185 
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debris, and subsequently stored at -80°C until further processing. Biopsies were 186 
subjected to NGS-based PGT-A (as detailed above), and results evaluated 187 
independently by three analysts blinded to the analysis profile of the original, 188 
clinically reported TE biopsy.  189 
For transparency, all karyotype profiles of every biopsy analyzed in this 190 





Whole blastocysts or biopsies were immersed in fixation buffer containing 4% 196 
paraformaldehyde (EMS #15710) and 10% fetal bovine serum (FBS) (Seradigm 197 
1500-050) in phosphate buffered saline (PBS) (Corning MT21040CM) for 10 198 
minutes (min) at room temperature (rt), followed by three 1 min washes at rt in 199 
stain buffer, composed of 0.1% Triton X-100 (TX-100) (Sigma X100-100ML) and 200 
10% FBS in PBS. Samples were then immersed in permeabilization buffer (0.5% 201 
TX-100, 10% FBS in PBS) for 30 min at rt, followed by three washes in stain 202 
buffer. Samples were then exposed to stain buffer containing both primary 203 
antibodies each in 1:200 concentrations over night at 4°C rocking on a nutator. 204 
Primary antibodies were mouse anti-human GATA3 (Thermo Fisher MA1-028) 205 
and rabbit anti-human OCT4A (Cell Signaling #2890). The next day, after three 206 
washes in stain buffer, samples were immersed in stain buffer containing both 207 
secondary antibodies each in 1:500 concentrations for 2-3 hours at rt. Secondary 208 
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antibodies were goat anti-mouse IgG AlexaFluor488 (Thermo Fisher A11029) 209 
and goat anti-rabbit IgG AlexaFluor647 (Thermo Fisher A21245). After three 210 
washes in stain buffer, samples were exposed to nuclear stain (Hoechst 33342, 211 
Thermo Fisher H3570) diluted at 1:1000 in stain buffer for 30 min at rt, followed 212 
by three more washes in stain buffer. Samples were placed in glass bottom 213 
dishes (MatTek P35G-1.5-20-C) in small drops of stain buffer overlaid with 214 
mineral oil (Sigma M5904), and imaged with a LSM 780 Confocal microscope 215 
(Zeiss).  216 
 217 
 218 
Analysis of tissue relatedness 219 
In cases of clinical TE-ICM karyotype discordance we confirmed tissue 220 
relatedness by a DNA fingerprinting method that utilizes SNP analysis and 221 
linkage disequilibrium known as ‘Tilde’ (Vohr et al., 2015). A full explanation of 222 
the adaptation of this method to PGT-A samples with low coverage NGS is 223 
detailed in Supplemental Data 1.  224 
 225 
Statistical analysis of correlation between morphology and karyotype 226 
discordance 227 
Analysis and graph preparation were performed in Prism 6 (GraphPad). 228 
Differences between groups were assessed by Chi-square test for trend with 229 
95% confidence levels. Significance was defined when P < 0.05. 230 
  231 
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Isolation of ICM and Second TE Biopsies 235 
We adopted a modified ICM-biopsy procedure previously outlined (Taylor 236 
et al., 2016), which permitted us to collect an ICM biopsy and subsequently a 237 
second TE biopsy in blastocysts (Fig. 1A and Video 1). Immunofluorescence was 238 
used to confirm accurate isolation of intended cells. In whole blastocysts the 239 
pluripotency factor OCT4 was present at high levels in the ICM and low levels in 240 
the TE, while GATA3 was exclusively expressed in cells of the TE as previously 241 
shown (Deglincerti et al., 2016). Analysis of matched TE-ICM biopsies from 12 242 
blastocysts indicated that both biopsy types exclusively contained cells of their 243 
intended lineage and were devoid of contamination from the other cell type (Fig. 244 
1B and Supplemental Fig. 1). Nuclear counterstain by Hoechst did not reveal any 245 
cells with fragmenting or apoptotic nuclear material, suggesting that the biopsy 246 
technique did not disrupt individual cells (Fig. 1B and Fig. S1). On average, TE 247 
biopsies comprised 7.6 cells (+/- 1.3 SD) while ICM biopsies comprised 7.3 cells 248 
(+/- 2.0 SD).  249 
 250 
Clinical TE-ICM Biopsy Concordant Blastocysts 251 
Of the 100 blastocysts originally classified as aneuploid by clinical 252 
(original) TE biopsy, 93 had ICMs that were also classified as aneuploid, which 253 
we denote as aneuploid-aneuploid concordant (Fig. 2 and Table I). Importantly, 254 
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when only considering blastocysts with whole chromosomal aneuploidies (single 255 
or multiple) in their clinical TE biopsies, aneuploidy in the ICM was present in 90 256 
out of 93 cases (96.8%). On the other hand, when considering blastocysts with 257 
only segmental (sub-chromosomal) aneuploidies in their clinical TE biopsies, 258 
aneuploidy in the ICM was present in only 3 out of 7 cases (42.9%).  259 
In aneuploid-aneuploid concordant blastocysts, analysis of second TE 260 
biopsies showed aneuploidy in 86 out of 88 cases, equaling 97.7% (Table I). The 261 
remaining two samples showed a mosaic pattern in their respective second TE 262 
biopsies. In five samples a second TE biopsy could not be retrieved.  263 
The 93 clinical TE-ICM aneuploid-aneuploid concordant blastocysts could 264 
be further subdivided in two groups. 79 were blastocysts that had perfectly 265 
matching karyotypes in the clinical TE and ICM biopsies (i.e., all the same 266 
chromosomes possessed the same aneuploidies in both tissues), which we 267 
denoted as aneuploid-aneuploid perfect concordant (Fig. 2, Table I, and for the 268 
karyotypic profiles see Supplemental Fig. 2). Such instances are likely 269 
consequences of meiotic errors, as the identical aneuploidy is present in both TE 270 
and ICM tissues (see Supplemental Data 2 for more detailed interpretations). 271 
The remaining 14 out of 93 blastocysts had dissimilar aneuploidies in the 272 
clinical TE and ICM biopsies, which we denoted as aneuploid-aneuploid 273 
imperfect concordant (Fig. 2, Table I, and for the karyotypic profiles see 274 
Supplemental Fig. 2). Interestingly, most such blastocysts (10 out of 14) showed 275 
the same aneuploid chromosome(s) in the ICM biopsy as the clinical TE biopsy 276 
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(presumed consequence of meiotic error), but contained additional mosaic 277 
events in the ICM (resulting from mitotic error), often segmental in nature.  278 
See Supplemental Data 2 for interpretations of chromosomal error 279 
etiologies in samples of the aneuploid-aneuploid imperfect concordant group.  280 
   281 
Clinical TE-ICM Biopsy Discordant Blastocysts 282 
Of the 100 blastocysts tested, we observed two cases in which the clinical 283 
TE biopsy was uniformly aneuploid but the ICM was mosaic (Fig. 2, Table I, and 284 
for the karyotypic profiles see Fig. 3) Supplemental Data 2 contains more 285 
detailed interpretations of their karyotypes.  286 
 Five out of 100 blastocysts had euploid ICMs while their clinical TE 287 
biopsies contained aneuploidies (Fig. 2, Table I, and for the karyotypic profiles 288 
see Fig. 3). Blastocyst #96 was the only case in which the clinical TE biopsy had 289 
a whole chromosomal aneuploidy (gain of chromosome 12, note that the 290 
karyotype profile enters into the 2.8-3.0 copy number region) but displayed 291 
euploidy in the ICM as well as in the second TE biopsy. 292 
The remaining four samples (blastocysts #97-#100) contained segmental 293 
aneuploidies in their original TE biopsies, but euploid ICM biopsies. For 294 
blastocyst #97, the clinical and second TE biopsies contained the same 295 
segmental aneuploidy, thereby suggesting euploidy confined to the ICM. This 296 
would be consistent with a mitotic event happening before or at the time of 297 
lineage segregation but in the progenitor cell of a large part of the TE. 298 
Blastocysts #98 and #99 displayed mosaicism in their respective second TE 299 
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biopsies, revealing the occurrence of mitotic errors in the TE lineage. For one 300 
blastocyst (#100), the second TE biopsy did not yield results due to a failed WGA 301 
reaction. (Global WGA failure rate for this study is 1 out of 221, or 0.4%). In total, 302 
of the clinical TE-ICM discordant blastocysts (aneuploid-euploid or aneuploid-303 
mosaic) yielding information in the second TE biopsy, only 2 out of 6  (33.3%) 304 
were uniformly aneuploid.    305 
In cases of clinical TE-ICM biopsy discordance, there existed the 306 
possibility of sample contamination or mislabeling. Notably, in the 100 embryos 307 
tested, the sex chromosomes (XX or XY) were always concordant between 308 
biopsies taken within the same blastocyst. Further, for each of the seven 309 
blastocysts that produced discordant results, we performed DNA fingerprinting to 310 
confirm that the clinical TE and ICM biopsies were derived from the same 311 
respective embryos (Fig. 4 and Supplemental Fig. 3). 312 
 Finally, we determined whether poor blastocyst morphology impacted 313 
karyotype discordance. The analysis indicated that neither blastocyst stage nor 314 
ICM/TE grade affected the likelihood of intra-blastocyst karyotype inconsistencies 315 
(Supplemental Fig. 4).  316 
 317 
 318 
  319 
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DISCUSSION 320 
 321 
Some parties have argued that PGT-A should not be performed under any 322 
circumstance and one of the criticisms of the technology questions whether a 323 
clinical TE biopsy is a valid genetic representative of the embryo (Esfandiari et 324 
al., 2016; Mastenbroek and Repping, 2014; Sermon et al., 2016). A study basing 325 
its rationale on mathematical modeling has claimed that a typical TE cell biopsy 326 
cannot determine embryo ploidy accurately enough for clinical use (Gleicher et 327 
al., 2017). One of the ensuing concerns that has been expressed is the 328 
possibility of erroneously discarding viable embryos (Practice Committees of the 329 
American Society for Reproductive et al., 2018). Here however, we provide 330 
experimental evidence using NGS that a TE biopsy classified as aneuploid is 331 
commonly predictive of aneuploidy in the ICM. In our experience, a whole 332 
chromosome aneuploidy in a clinical TE biopsy is predictive of aneuploidy in the 333 
ICM in 96.8% of cases (sample size n=93), although for a segmental aneuploidy 334 
this decreases significantly to 42.9% (n=7). 335 
 A blastocyst with an aneuploid TE and ICM due to meiotic error is in 336 
principle exceptionally unlikely to result in healthy pregnancy (Adashi and 337 
McCoy, 2017). Although various corrective mechanisms for aneuploidies in 338 
human embryos have been proposed (differential proliferation/depletion, 339 
preferential lineage allocation, self-correction) (Capalbo and Rienzi, 2017; 340 
McCoy, 2017) and have also been conceptually demonstrated in mouse embryos 341 
(Bolton et al., 2016) and human embryonic stem cells (hESC) (Munne et al., 342 
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2005), most models describe the out-competition of aneuploid cells by euploid 343 
cells in the mosaic setting, not the conversion of an entirely aneuploid embryo to 344 
an entirely euploid one.  345 
The observation that segmentals had a drastically different rate of clinical 346 
TE-ICM discordance compared to whole chromosome aneuploids highlights the 347 
difference in mechanistic origins of these two types of aneuploidies. Whole 348 
chromosome aneuploidies can arise during meiosis or mitosis by different 349 
mechanisms that include non-disjunction, anaphase lag, and endoreplication 350 
(Taylor et al., 2014), but the majority are believed to be derived from meiotic 351 
errors in the oocyte (Nagaoka et al., 2012). The majority of segmental 352 
aneuploidies on the other hand are mitotic in origin and are thought to arise 353 
during the first few cell divisions after fertilization (Babariya et al., 2017). Cell 354 
cycle control is thought to be more lax during the first days of embryogenesis due 355 
to rapid mitoses primarily controlled by maternal RNA and proteins, leading to an 356 
increased incidence of double strand breaks which upon faulty correction 357 
mechanisms result in segmental duplications or deletions when left unresolved 358 
by a strained cell cycle machinery (Babariya et al., 2017). Consequently, 359 
segmental aneuploidies will often be represented in mosaic configurations at a 360 
whole blastocyst level, likely translating in the high TE-ICM discordance rate 361 
observed for the segmental aneuploidy group in this study. 362 
Out of 93 blastocysts with whole chromosome aneuploidies (single or 363 
multiple) in a clinical TE biopsy, three embryos had a discordant ICM: two 364 
contained mosaic ICM biopsies, and one had a euploid ICM. Consequently, the 365 
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karyotype of these three blastocysts should be re-classified from aneuploid to 366 
mosaic, since on a whole embryo level they contained aneuploid and euploid 367 
cells. This re-categorization would have changed the status of the blastocysts 368 
from ‘not recommended for transfer’ to ‘possible transfer if no euploid embryos 369 
available’. Mosaic embryos have recently been considered for transfer in several 370 
clinics, producing healthy pregnancies albeit with considerably lower implantation 371 
rates than blastocysts classified as euploid (Fragouli et al., 2017; Lledo et al., 372 
2017; Munne et al., 2017; Spinella et al., 2018).  373 
From a clinical standpoint, our findings may support re-biopsy of 374 
blastocysts in patients that have only produced embryos classified as aneuploid 375 
(particularly segmentals) by initial TE biopsy after repeated IVF cycles, an 376 
occurrence that happens with relative frequency especially with advanced 377 
maternal age (Franasiak et al., 2014). It could also affect those patients that have 378 
unsuccessfully transferred their embryos classified as ‘euploid’ and ‘mosaic’, and 379 
only have ‘aneuploid’ samples remaining. In our study, all blastocysts had an 380 
initial, clinical TE biopsy that was uniformly aneuploid. When a second TE biopsy 381 
was either mosaic or euploid, such a blastocyst had a 66% chance to contain an 382 
ICM that was either mosaic or euploid as well. On the other hand, in cases where 383 
the second TE biopsy was aneuploid, the ICM was mosaic in only 1.1% of cases, 384 
and there were no euploid ICM instances. Therefore, our results suggest that TE 385 
re-biopsy can reveal whether the ICM is mosaic or euploid, helping to identify 386 
new blastocysts for possible clinical use that were originally not recommended 387 
for transfer due to aneuploidy in the clinical TE biopsy. Importantly, while the act 388 
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of re-biopsy might negatively affect blastocysts, re-biopsied blastocysts can lead 389 
to healthy pregnancies albeit with lower efficiency than single-biopsied 390 
blastocysts (Bradley et al., 2017). Nevertheless, more research is necessary to 391 
determine the short and long term effects of TE re-biopsy, and recommendation 392 
of routine re-biopsy of blastocysts classified as aneuploid is undoubtedly 393 
premature.   394 
The confirmed existence of clinical TE-ICM discordant embryos could also 395 
help explain the rare accounts of healthy pregnancies resulting from transfer of 396 
embryos classified as aneuploid by PGT-A (Gleicher et al., 2016), although it 397 
must be pointed out that to our knowledge, there exist no reports of such events 398 
when using blastocyst stage NGS-based PGT-A.  399 
It is important to note that our determined rates of clinical TE-ICM 400 
concordance apply specifically to blastocysts classified as ‘uniform aneuploid’ (no 401 
mosaics) by PGT-A. Having observed an overall 7% clinical TE-ICM discordance 402 
rate in our samples, we cannot assume the inverse: that 7% of blastocysts 403 
classified as euploid contain an aneuploid ICM. A further intriguing and clinically 404 
important question is what a clinical TE biopsy showing mosaicism says about 405 
the ICM. Unfortunately, our study cannot shed light on that point.  406 
A further limitation of this study was that not all cells were analyzed for 407 
intra-blastocyst karyotypic concordance. The ICM biopsies isolated (averaging 408 
7.3 cells) collected the bulk of ICM cells but invariably left residual ICM cells 409 
behind. On average, we collected 15 TE cells from the two combined TE biopsies 410 
of each blastocyst, hence a substantial portion of the TE was left unanalyzed. 411 
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From the technical standpoint we were unable to isolate more cells from a 412 
specific tissue without contamination from the other lineage. As a result, 413 
instances of karyotype discordance could remain concealed.      414 
While highly controversial, the concept of transferring embryos testing 415 
aneuploid by PGT-A is a real subject of discussion in both scientific (Gleicher et 416 
al., 2016) and mainstream media (Hall, 2017). The upheaval created by these 417 
viewpoints has partly been bolstered by the yet unspecified capability of a single 418 
clinical TE biopsy to reflect the state of the ICM and remaining TE. With regard to 419 
this question our findings contribute experimental validation on the practice of 420 
PGT-A at the blastocyst stage, considering the high intra-blastocyst aneuploidy 421 
concordance rates, especially in the case of whole chromosome losses or gains. 422 
If indeed the group of blastocysts analyzed in this study is representative of the 423 
general body of IVF blastocysts, it would mean that when selecting an embryo 424 
classified as ‘aneuploid’ by PGT-A for uterine transfer, it almost always contains 425 
aneuploidy in the entire blastocyst. Unless robust self-correction mechanisms do 426 
in fact exist, said embryo would invariable lead to failed implantation, 427 
miscarriage, or chromosomally abnormal babies. Segmental aneuploidies on the 428 
other hand are rarely concordant; if our observations are confirmed in a larger 429 
sample group they should be regarded as their own distinct class when 430 
prioritizing or de-selecting embryos for transfer in the clinic. 431 
 432 
 433 
  434 
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 451 
FIGURE LEGENDS 452 
 453 
Figure 1.  454 
Validation of biopsy and PGT-A methods used in the study  455 
 456 
(A) Stills from video depicting isolation of ICM biopsy in blastocysts. 457 
The blastocyst is immobilized with a holding pipet touching the 458 
polar TE (adjacent to the ICM), and laser pulses are 459 
administered through the zona and mural TE opposite the ICM 460 
creating an opening. A biopsy pipette is introduced and guided 461 
to the ICM, which is suctioned out through the opening. Once a 462 
portion of ICM cells are extracted past the zona, they are 463 
exposed to laser pulses aimed at cell-cell junctions to isolate a 464 
5-10 cell biopsy.  465 
 466 
(B) Nuclear counterstain (Hoechst) and immunofluorescent stains 467 
for the TE marker GATA3 and ICM marker OCT4 in a whole 468 
human blastocyst and isolated TE and ICM biopsies. See 469 
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Figure 2.  474 
Summary of paired clinical TE-ICM comparison results  475 
 476 
Dot plot displays results for all blastocysts, regardless of aneuploidy type. 477 
Pie charts depict data stratified by nature of aneuploidy detected in the 478 
original TE biopsy for each blastocyst.   479 
 480 
 481 
Figure 3.  482 
NGS-based PGT-A karyotype profiles for biopsies in blastocysts with 483 
discordant clinical TE-ICM patterns 484 
  485 
See Table I for the interpretation of each profile.   486 
 487 
 488 
Figure 4. 489 
Log-likelihood ratios of relatedness between tissues in blastocysts 490 
with clinical TE-ICM discordance  491 
 492 
In green, controls comparing biopsies from embryos derived from patients 493 
expected to be unrelated, showing negative values. In red, comparisons 494 
between biopsies from blastocysts derived from the same patient (full-495 
sibs) showing positive values. In purple, comparisons between clinical TE 496 
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and ICM biopsies for each blastocyst classified as discordant in the study, 497 
showing highly positive log-likelihood ratios of relatedness. 498 
 499 
Supplemental Figure 1. 500 
Validation of contamination-free ICM and TE biopsy technique 501 
 502 
Nuclear counterstain (Hoechst) and immunofluorescent stains for the TE 503 
marker GATA3 and ICM marker OCT4 in matched isolated TE and ICM 504 
biopsies. Numbers in nuclear stain panels indicate total number of cells for 505 
each biopsy. Numbers in TE stain panels indicate incidence of cells 506 
positive for GATA3. Numbers in ICM stain panels indicate incidence of 507 
cells with high nuclear signal for OCT4. Scale bars = 25µm.  508 
!509 
 510 
Supplemental Figure 2. 511 
Karyotype profiles analyzed in this study (continued from Fig. 3) 512 
  513 
Use Table I as a reference for resulting analysis.  514 
 515 
 516 
Supplemental Figure 3. 517 
Genotypes of discordant blastocysts visualized in reference ancestry 518 
space 519 
 520 
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Supplemental Figure 4 521 
Analysis of correlation between morphology and intra-blastocyst 522 
karyotype discordance  523 
Blastocysts were evaluated using the Gardner system, that assigns a 524 
number score for blastocyst expansion stage (1-6 from least to most 525 
progressed), and letter scores for ICM and TE grades (C-A from worst to 526 
best quality) (Gardner and Schoolcraft, 1999). Stage of blastocyst was 527 
analyzed when there was any intra-blastocyst karyotype inconsistency (A), 528 
when an inconsistency was specific to the ICM (B), and when an 529 
inconsistency was specific to the TE (C). Grade of the ICM was analyzed 530 
when there was any karyotype inconsistency between clinical TE biopsy 531 
and the ICM (D). Grade of the TE was analyzed when there was any 532 
karyotype inconsistency between clinical TE and second TE biopsy (E). 533 
Note that in graphs A, C, and D, sample numbers do not add up to 100 534 
because in six cases the second TE biopsy was not processed (in five 535 
cases the biopsy could not be collected, and in one case there was a 536 
failed WGA reaction. 537 
  538 
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 539 
TABLE LEGENDS 540 
 541 
Table I. List of blastocysts, clinical TE, ICM, and second TE biopsies analyzed in 542 
this study. 543 
 544 
 545 
Supplemental Table I. Blastocysts and assigned 1000 Genomes super-546 
populations. 547 
 548 
Supplemental Data 1. Adaptation of ‘Tilde’ to PGT-A samples with low coverage 549 
NGS. 550 
 551 
Supplemental Data 2. Additional interpretations of chromosomal error etiologies 552 
in blastocysts.  553 
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TABLE I
Clinical TE-ICM Aneuploid-Aneuploid Perfect Concordant Clinical TE-ICM Aneuploid-Aneuploid Imperfect Concordant
Blastocyst Study id# Gardner Grade Clinical TE Biopsy ICM Biopsy Second TE Biopsy Blastocyst Study id# Gardner Grade Clinical TE Biopsy ICM Biopsy Second TE Biopsy
1 4BB 45,XY,-4 45,XY,-4 45,XY,-4 80 4AC 45,XX,-14 45,XX,-14,del(1)(p36.32p36.12)* 45,XX,-14
2 4BB 45,XX,-7 45,XX,-7 45,XX,-7 81 4BB 45,XY,-16 45,XY,-16,dup(2)(p25.3p23.1)* 45,XY,-16
3 5BB 45,XX,-8 45,XX,-8 46,XX,-8*,+15*,+20* 82 4AA 45,XY,-18 45,XY,-18,dup(2)(q23.3q37.3)*  45,XY,-18
4 3AB 45,XY,-8 45,XY,-8 45,XY,-8 83 5BA 45,XY,-21 45,XY,-21,dup(18)(p11.32q12.1)* 45,XY,-21
5 5BC 45,XX,-10 45,XX,-10 45,XX,-10 84 3BC 45,XX,-22 45,XX,-15*,-22 45,XX,-22
6 4BB 45,XY,-11 45,XY,-11 45,XY,-11 85 4BC 45,X 45,X,+20*,+21* 45,X,+2*,+14*
7 5BB 45,XX,-13 45,XX,-13 45,XX,-13 86 4BB 47,XX,+16 47,XX,+16,dup(5)(q12.1q35.1)* 47,XX,+16
8 5BC 45,XY,-13 45,XY,-13 n/a 87 5BB 47,XY,+20 47,XY,+20,del(1)(p36.33p33)* 47,XY,+20
9 5BC 45,XY,-14 45,XY,-14 45,XY,-14 88 5CC 46,XX,-10,+15 48,XX,-10*,+15,+17 46,XX,-10,+15
10 4BB 45,XY,-14 45,XY,-14 45,XY,-14 89 4BC 44,XX,-15,-22 44,XX, -15,+18*,-22,dup(1)(q12q44)* 44,XX,-15,-22
11 2BB 45,XX,-15 45,XX,-15 45,XX,-15 90 5BB 44,XY,-21,-22 44,XY,-21,-22,del(1)(p36.33p33)* 44,XY,-21,-22
12 4BC 45,XX,-15 45,XX,-15 n/a 91 5BC 47,XX,+4,+9,-13 47,XX,+3*,+4,+7*,+9,-13 47,XX,+3*,+4,+7*,+9,-13
13 3BB 45,XX,-16 45,XX,-16 45,XX,-16 92 5CC 47,XX,+20,del(2)(p25.3p24.1) 47,XX,+20,del(2)(p25.3p24.1)* 47,XX,+20,del(2)(p25.3p24.1)
14 4BC 45,XX,-16 45,XX,-16 45,XX,-16 93 5BB 46,XX,del(16)(p13.3p11.2) 45 XX,-16 46,XX,del(16)(p13.3p11.2),dup(16)(p11.2p24.3)*
15 4BB 45,XX,-16 45,XX,-16 45,XX,-16
16 4BB 45,XY,-16 45,XY,-16 45,XY,-16
17 5CC 45,XY,-16 45,XY,-16 45,XY,-16
18 5CC 45,XX,-17 45,XX,-17 45,XX,-17
19 5AB 45,XY,-18 45,XY,-18 45,XY,-18,del(10)(q11.21q26.3)* Clinical TE-ICM Aneuploid-Mosaic Discordant
20 4BB 45,XX,-21 45,XX,-21 45,XX,-21 Blastocyst Study id# Clinical TE Biopsy ICM Biopsy Second TE Biopsy
21 5BB 45,XX,-21 45,XX,-21 45,XX,-21 94 4BC 45,XY,-19 46,XY,-19* 45,XY,-19
22 4CB 45,XY,-21 45,XY,-21 45,XY,-21 95 5AB 47,XY,+6 46,XY,del(4)(q32.1q35.2)* 46,XY
23 5BB 45,XX,-22 45,XX,-22 45,XX,-22
24 4BB 45,XX,-22 45,XX,-22 45,XX,-22
25 5BB 45,XY,-22 45,XY,-22 45,XY,-22
26 4BB 45,XY,-22 45,XY,-22 45,XY,+4*,-22 Clinical TE-ICM Aneuploid-Euploid Discordant
27 4AA 45,XY,-22 45,XY,-22 45,XY,-22 Blastocyst Study id# Clinical TE Biopsy ICM Biopsy Second TE Biopsy
28 4BB 45,X 45,X 46,XX,dup(X)(p22.33p21.1),dup(X)(q22.3q25)* 96 4AB 47,XX,+12 46,XX 46,XX
29 5BC 47,XX,+1 47,XX,+1 47,XX,+1 97 4BB 46,XX,del(2)(q22.1q31.1) 46,XX 46,XX,del(2)(q22.1q31.1)
30 4BC 47,XY,+4 47,XY,+4 47,XY,+4 98 4BB 46,XY,dup(3)(q26.2q29)(x2) 46,XY 46,XY,dup(3)(q26.2q29)*,dup(22)(q11.1q13.31)* 
31 4AB 47,XX,+13 47,XX,+13 47,XX,+13 99 4AB 46,XX,del(9)(q12q34.3) 46,XX 46,XX,del(9)(q12q34.3)*
32 3BB 47,XX,+13 47,XX,+13 47,XX,+13 100 3BB 46,XX,dup(11)(q23.2q25) 46,XX n/a
33 5AA 47,XY,+15 47,XY,+15 47,XY,+15
34 4CB 47,XX,+16 47,XX,+16 47,XX,+16
35 3AB 47,XX,+16 47,XX,+16 47,XX,+16
36 5BB 47,XX,+16 47,XX,+16 n/a
37 5BB 47,XY,+16 47,XY,+16 47,XY,+16 * MOSAIC
38 4BB 47,XY,+16 47,XY,+16 47,XY,+16
39 4BC 47,XY,+16 47,XY,+16 47,XY,+16
40 5BB 47,XY,+17 47,XY,+17 47,XY,-10*,+17
41 4BB 47,XY,+18 47,XY,+18 47,XY,+18
42 4CB 47,XY,+18 47,XY,+18 47,XY,+18
43 5BB 47,XY,+19 47,XY,+19 47,XY,+19
44 5AB 47,XX,+20 47,XX,+20 47,XX,+20
45 4BC 47,XX,+21 47,XX,+21 47,XX,+21
46 5CB 48,XX,+21(x2) 48,XX,+21(x2) 48,XX,+21(x2)
47 4BB 47,XX,+22 47,XX,+22 47,XX,+22
48 4AA 47,XX,+22 47,XX,+22 47,XX,+22
49 5AB 47,XX,+22 47,XX,+22 47,XX,+22
50 4BB 47,XY,+22 47,XY,+22 47,XY,+22
51 5CC 47,XY,+22 47,XY,+22 47,XY,+22
52 4BC 47,XY,+22 47,XY,+22 47,XY,+22
53 3CC 47,XY,+22 47,XY,+22 47,XY,+22,del(1)(q25.2q44)
54 3BB 44,XY,-10,-22 44,XY,-10,-22 44,XY,-10,-22
55 4BB 46,XX,-12,+16 46,XX,-12,+16 46,XX,-12,+16
56 4CC 44,XX,-14,-19 44,XX,-14,-19 44,XX,-14,-19
57 4BB 44,XY,-18,-21 44,XY,-18,-21 44,XY,-18,-21
58 4BC 46,XY,-19,+22 46,XY,-19,+22 n/a
59 5BB 46,XY,-21,+22 46,XY,-21,+22 46,XY,-21,+22
60 5CB 48,XY,+2,+3 48,XY,+2,+3 48,XY,+2,+3
61 4BB 46,XY,+3,-22 46,XY,+3,-22 n/a
62 4AA 48,XX,+5,+9 48,XX,+5,+9 48,XX,+5,+9
63 4AC 46,XX,+6,-15 46,XX,+6,-15 46,XX,+6,-15
64 5BB 48,XY,+8,+16 48,XY,+8,+16 48,XY,+8,+16,del(2)(q21.1q37.3)*
65 3BB 48,XX,+9,+16 48,XX,+9,+16 48,XX,+9,+16
66 3BB 48,XX,+9,+22 48,XX,+9,+22 48,XX,+9,+22
67 4BB 48,XX,+10,+18 48,XX,+10,+18 48,XX,+10,+18
68 5AB 48,XY,+16,+21 48,XY,+16,+21 48,XY,+16,+21
69 5BB 46,XX,+18,-22 46,XX,+18,-22 46,XX,+18,-22
70 3BA 45,XX,-11,+12,-21 45,XX,-11,+12,-21 45,XX,-11,+12,-21
71 4CB 47,XY,+1,-13,+21 47,XY,+1,-13,+21 47,XY,+1,-13,+21
72 3BB 47,XY,+11,+18,-20 47,XY,+11,+18,-20 47,XY,+11,+18,-20
73 5BC 47,XY,+14,-15,+19 47,XY,+14,-15,+19 47,XY,+14,-15,+19
74 5BC 49,XX,+16,+18,+19 49,XX,+16,+18,+19 48,XX,+16,+18,+19*
75 4AB 48,XX,-2,+3,+9,+22 48,XX,-2,+3,+9,+22 48,XX,-2,+3,+9,+22
76 5BA 46,XY,+3,+4,-18,-21 46,XY,+3,+4,-18,-21 46,XY,+3,+4,-18,-21
77 5CB 47,XY,+16,del(20)(q13.2q13.33) 47,XY,+16,del(20)(q13.2q13.33) 47,XY,-1*,+16,-20*,del(5)(q23.1q35.3)*
78 4AB 46,XY,del(6)(q16.1q27) 46,XY,del(6)(q16.1q27) 46,XY,del(6)(q16.1q27)*
79 4BC 46,XX,del(1)(q43q44) 46,XX,del(1)(q43q44) 46,XX,del(1)(q43q44)
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Paired clinical TE-ICM Biopsy Status
Aneuploid-Euploid Discordant
FIG2
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K = 10 Nearest Neighbors 
1000 Genomes Reference 
Panel Super-Population 
ICM TE 
#94 C/S Asia C/S Asia SAS 
#95 C/S Asia C/S Asia SAS 
#96 East Asia East Asia EAS 
#97 Europe Middle East EUR 
#98 East Asia East Asia EAS 
#99 East Asia East Asia EAS 




Page 79 of 87
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
Supplemental Data 1 
 
 
Analysis of tissue relatedness 
 
‘Tilde’ (Vohr et al., 2015) was used to rule out sample cross-contamination or 
mislabeling and infer, based on low-coverage sequencing data, whether ICM and 
TE biopsies were derived from the same blastocyst. This method facilitates 
indirect comparison of low-coverage samples based on the principle that sparse 
observed genotypes are informative of genotypes at nearby unobserved markers 
due to patterns of linkage disequilibrium (LD) in the population. 
Reads were mapped to the hg19 reference using the BWA (version 
0.7.17) backtrack algorithm with default parameters (Li and Durbin, 2009). We 
then used the LASER method (version 2.04; (Wang et al., 2015)) to select the 
appropriate ethnically matched 1000 Genomes Project super-population 
(Genomes Project et al., 2015) for each blastocyst, as required by tilde. LASER 
combines genotype imputation with principal components analysis to infer 
individual ancestry based on low-coverage sequence data. Blastocyst genotypes 
were visualized in reference ancestry space defined by principal components 
analysis of the HGDP reference panel (Supplemental Fig. 4; (Li et al., 2008)). 
Blastocysts were then assigned to corresponding 1000 Genomes super-
populations based on ancestries of the K=10 nearest neighbor reference 
samples in principal components space (Supplemental Table I). In the case of 
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blastocyst #97, whose ICM and TE biopsies were assigned to European and 
Middle Eastern reference populations, respectively, we selected the European 
super-population as the reference panel. We note that these populations fall 
close to one another in space defined by the top three principal components. 
Furthermore, Vohr et al. (2015) demonstrated that tilde is relatively robust to 
misspecification of the reference panel. 
Tilde computes a log-likelihood ratio comparing a model in which two 
samples are derived from the same individual (i.e., same embryo) to a model in 
which two samples are derived from unrelated individuals (i.e., different 
embryos). Positive log-likelihood ratios indicate that the data support the former 
model, while negative log-likelihood ratios indicate that the data support the latter 
model. Bootstrapping was performed to generate distributions and assess 
uncertainty in log-likelihood ratio estimates. 
As controls, we applied this method to twenty-four comparisons of 
presumed unrelated embryos as well as four comparisons of full sibling (full-sib) 
embryos obtained from the same patient. Results from the unrelated negative 
controls supported the capacity of tilde to distinguish these samples, reflected by 
negative distributions of log-likelihood ratios (Fig. 4). For all seven embryos 
producing discordant TE-ICM results, the data supported a model in which the 
samples were derived from the same corresponding embryo, reflected by 
positive distributions of log-likelihood ratios. Meanwhile, the full-sib samples from 
the same patient also produced positive distributions of log-likelihood ratios, but 
intermediate between the unrelated and same-embryo comparisons, supporting 
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the power of tilde to distinguish varying levels of relatedness. Together, our data 
suggest no evidence of cross-contamination or sample mislabeling and 
substantiate the conclusion that the TE and ICM biopsies of discordant karyotype 
were derived from the same respective embryos. More generally, our analysis 
demonstrates that methods such as tilde, which take advantage of patterns of LD 
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